Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 1 1

Status

Withdrawn 1Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Leukemia, Myeloid, Acute 197Leukemia 110Lymphoma 90Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Burkitt Lymphoma 52Myelodysplastic Syndromes 47Lymphoma, Mantle-Cell 47Lymphoma, Large B-Cell, Diffuse 47Lymphoma, Non-Hodgkin 46Leukemia, Myelomonocytic, Acute 30Lymphoma, Follicular 29Leukemia, Monocytic, Acute 29Recurrence 25Congenital Abnormalities 25Leukemia, Erythroblastic, Acute 24Lymphoma, Large-Cell, Immunoblastic 23Leukemia, Megakaryoblastic, Acute 23Blast Crisis 21Hodgkin Disease 20Leukemia, Lymphocytic, Chronic, B-Cell 18Leukemia, Myelomonocytic, Chronic 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Lymphoma, B-Cell, Marginal Zone 15Anemia, Refractory, with Excess of Blasts 15Leukemia, Myeloid, Accelerated Phase 13Leukemia, Biphenotypic, Acute 13Leukemia, Myeloid, Chronic-Phase 12Dendritic Cell Sarcoma, Interdigitating 12Myeloproliferative Disorders 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10

Interventions

Cyclophosphamide 23Prednisone 16N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Vincristine 11Doxorubicin 11Etoposide 9fludarabine phosphate 8Whole-Body Irradiation 8Mycophenolic Acid 7Lenalidomide 7Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6Brentuximab Vedotin 6Azacitidine 6Alemtuzumab 6Cyclosporine 5Bortezomib 5romidepsin 4fludarabine 4Tacrolimus 4Rituximab 4Methotrexate 4Granulocyte Colony-Stimulating Factor 4Cytarabine 4pembrolizumab 3denileukin diftitox 3Transplantation 3Dexamethasone 3Carmustine 3Busulfan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell, Peripheral × Cytarabine × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT06468267 2024-08-01

RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
50 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03629873 2022-01-03

Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
69 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell

NCT00632827 2020-04-27

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

University of California, San Francisco

Phase 2 Terminated
21 enrolled 13 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡